GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (FRA:7CA) » Definitions » Additional Paid-In Capital

Camurus AB (FRA:7CA) Additional Paid-In Capital : €275.2 Mil(As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Camurus AB Additional Paid-In Capital?


Camurus AB's quarterly additional paid-in capital increased from Sep. 2023 (€170.7 Mil) to Dec. 2023 (€182.6 Mil) and increased from Dec. 2023 (€182.6 Mil) to Mar. 2024 (€275.2 Mil).

Camurus AB's annual additional paid-in capital declined from Dec. 2021 (€183.8 Mil) to Dec. 2022 (€179.5 Mil) but then increased from Dec. 2022 (€179.5 Mil) to Dec. 2023 (€182.6 Mil).

Camurus AB Additional Paid-In Capital Historical Data

The historical data trend for Camurus AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Additional Paid-In Capital Chart

Camurus AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 134.79 176.63 183.76 179.53 182.59

Camurus AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 176.69 171.16 170.70 182.59 275.16

Camurus AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Camurus AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Camurus AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Camurus AB (FRA:7CA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (FRA:7CA) » Definitions » Additional Paid-In Capital
Comparable Companies
OSTO:BIOA B OSTO:CALTX OSTO:GENO OSTO:VICO OSTO:EGTX OSTO:HNSA OSTO:IBT B OSTO:FLUO OSTO:BINV OSTO:XSPRAY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CAMX:Sweden
Address
Ideon Science Park, Lund, SWE, SE-223 70
Website
https://www.camurus.com
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The company's product pipeline includes CAM2038, CAM2029, CAM2032, and others. The company's geographical revenue includes Europe (of which Sweden), the United States of America, Australia, and Other geographical areas.

Camurus AB (FRA:7CA) Headlines

No Headlines